- About XNAT
- News & Events
- XNAT Marketplace
- Contact Us
Time: Day 1, 12:15 – 12:45 pm CDT
Host: Dave Cash, University College London
Panelists: Pam LaMontagne (CIL), Mark White (National Health Service UK), Marcel Koek (Erasmus MC)
When possible and as time permitted, questions that were brought up in the Q&A module during each talk were addressed in real time by the presenter. Other responses were entered in the Q&A interface itself. Those written responses are included below.
Would be good to have a list of trusts/ boards in NHS in UK with instances of XNAT running.
Also more sharing / curation of dicom anonymisation scripts that have been proven to be robust and the processes of how this was achieved. Would help me convince my information governance dept in NHS that running XNAT and using it as a vehicle for shipping data out is a safe thing to do
|With growing prevalence of malware attacks etc is there a security protocol/procedure you follow for quarantining incoming data from external sources to minimize risk?|
Most of the discussion so far has been about pulling data from clinic to researchers. I see translation as also going from research towards the patient. E.g. using XNAT to facilitate clinical evaluation of tools, collect data for healthcare economics
How do you think this (if deemed relevant) could be facilitated (safety, info compliance, r&d, etc)?
|Are there pipeline containers for running anonymisation checking? or plugins to implement these checks easily via the XNAT gui?|
|Has anyone done process or other work using XNAT in Clinical Trials and changes are being made to protocols (for example, eligiblity, or CRF changes) that may impact what's in XNAT?|